Preeclampsia Clinical Trial
— EVUPAOfficial title:
Utero-placental Vascularisation in Normal and Preeclamptic and Intra-uterine Growth Restriction Pregnancies: Third Trimester Quantification Using 3D Power Doppler With Comparison to Placental Vascular Morphology
NCT number | NCT02825277 |
Other study ID # | 2013-A01049-36 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | June 30, 2016 |
Last updated | July 4, 2016 |
Start date | December 2013 |
Introduction
Preeclampsia (PE) and intra-uterine growth restriction (IUGR) are two major pregnancy
complications related to chronic utero-placental hypoperfusion. Three-dimensional power
Doppler (3DPD) angiography has been used for the evaluation of utero-placental
vascularisation and three vascular indices have been calculated: the vascularisation index
(VI), flow index (FI) and vascularisation-FI (VFI). However, several technical endpoints
hinder the clinical use of 3DPD as physical characteristics and machine settings may affect
3DPD indices, and so its clinical significance is not yet clear.
Objectives
The primary objective is to better understand the clinical significance of 3DPD indices by
evaluating the relationship between these indices and placental morphometry. Secondary
objectives are (i) to determine the impact of machine settings and physical characteristics
on 3DPD indices, and (ii) to evaluate physio-pathological placental vascularisation
patterns.
Methods and analysis
This is a prospective controlled study. We expect to include 112 women: 84 with normal
pregnancies and 28 with PE and/or IUGR (based on our former cohort study on 3DPD indices for
PE and/or IUGR prediction (unpublished data)). Within 72 h before planned or semi-urgent
caesarean section, utero-placental 3DPD images with five different machine settings will be
acquired. Placentas will be collected and examined after surgery and stereological indices
(volume density, surface density, length density) calculated. The 3DPD indices (VI, FI and
VFI) of the placenta and adjacent myometrium will be calculated. Correlation between Doppler
and morphological indices will be evaluated by Pearson or Spearman tests. Agreement between
3DPD indices and morphological indices will be assessed by Bland and Altman plots. The
impact of Doppler settings and maternal characteristics on 3DPD indices will be evaluated
with a multivariate linear regression model.
Status | Recruiting |
Enrollment | 112 |
Est. completion date | |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility |
General Inclusion Criteria: - Age =18 years and =65 years Fetal anomalies - Gestational age =30 gestational weeks - With social insurance - With written consent for participation - With medical examination Physiological group Inclusion Criteria - Hospitalised pregnant women with scheduled or semi-urgent caesarean section according to national HAS recommendations or Hospitalised pregnant women with scheduled vaginal delivery. - Normal pregnancy issues - Normal fetal morphology Pathological group Inclusion Criteria - Pregnant women with preeclampsia and/or IUGR pregnancy - Hospitalised pregnant women with scheduled or semi-urgent caesarean section or hospitalised pregnant women with scheduled vaginal delivery. Exclusion Criteria: - Fetal morphological abnormalities that may influence fetal circulation - Maternal or fetal vital urgency - Multiple pregnancy - Non-placental origin IUGR - Language barrier - Patient under legal protection |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
France | Pr Olivier MOREL | Vandoeuvre les Nancy |
Lead Sponsor | Collaborator |
---|---|
Central Hospital, Nancy, France |
France,
Duan J, Chabot-Lecoanet AC, Perdriolle-Galet E, Christov C, Hossu G, Cherifi A, Morel O. Utero-placental vascularisation in normal and preeclamptic and intra-uterine growth restriction pregnancies: third trimester quantification using 3D power Doppler with comparison to placental vascular morphology (EVUPA): a prospective controlled study. BMJ Open. 2016 Mar 31;6(3):e009909. doi: 10.1136/bmjopen-2015-009909. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measure of 3D power Doppler indice : the vascularization index (VI) | through study completion, an average of 42 month | No | |
Primary | Measure of 3D power Doppler indice : blood flow (the flow index (FI) | through study completion, an average of 42 month | No | |
Primary | Measure of of 3D power Doppler indice : the vascularization-flow index (VFI) | through study completion, an average of 42 month | No | |
Primary | Measure of volume density (morphological analysis) | through study completion, an average of 42 month | No | |
Primary | Measure of surface density (morphological analysis) | through study completion, an average of 42 month | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |